Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wujun Zhidan Granules
- Development stage
- Unknown
- Lead developer
- Consun Pharmaceutical
- Administration
- Oral
01
Overview
Wujun Zhidan Granules (五军止胆颗粒) is a Traditional Chinese Medicine (TCM) product developed and manufactured by Conchen Pharmaceutical, a subsidiary of Consun Pharmaceutical Group. Formulated as oral granules, it is approved in China for the treatment of cholecystitis and biliary tract infections. As a TCM therapeutic, its mechanism of action is based on traditional principles such as clearing heat, resolving dampness, and promoting gallbladder function (choleretic effect) to alleviate inflammation and infection within the hepatobiliary system. It is recognized as a National New Drug in China.
- Brand names
- Wujun Zhidan Granules
- Other names
- 五军止胆颗粒Wujun Zhidan
Beyond the preview
Go deeper on Wujun Zhidan Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wujun Zhidan Granules.